Publication
Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.
Wenwen Cheng, Silvia Gaggero, Lama Hasan Bou Issa, Aïcha Ouelkdite, Guillaume Escure, Adeline Cozzani, Yanick Njosse Tchantchou, Noémie Carlier, Emilie Wauquier, Gauthier Decool, Rémi Tilmont, Benjamin Podvin, Malo Leprohon, Mojtaba Shekarkar, Léa Fléchon, Angélina Kasprowicz, Sophie Groux-Degroote, Jérôme Moreaux, Bertrand Arnulf, Jill Corre, Céline Villenet, Ludovic Martinet, Xavier Leleu, Martin Figeac, Thierry Facon, Wenfei Jin, Suman Mitra, Salomon Manier
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260908-000002
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Daratumumab-lenalidomide (DR) combination therapy improves multiple myeloma (MM) outcomes, yet some patients respond poorly. We examined 21 DR pre-treatment samples from the IFM2017-03 phase 3 trial using single-cell and bulk multiomics approaches to identify determinants of response. Analysis of…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available